首页 > 市场调查报告书 > 製药

癌症

癌胚抗原 (CEA) 市场规模、份额和成长分析（按类型、性别、产品类型、检测方法、最终用户和地区划分）—2026-2033 年产业预测

市场调查报告书

商品编码

1900692

癌胚抗原 (CEA) 市场规模、份额和成长分析（按类型、性别、产品类型、检测方法、最终用户和地区划分）—2026-2033 年产业预测

Carcinoembryonic Antigen Market Size, Share, and Growth Analysis, By Type (Colorectal Cancer, Pancreatic Cancer), By Gender (Male, Female), By Product, By Test, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，癌胚抗原 (CEA) 市场规模将达到 27.2 亿美元，到 2025 年将达到 28.6 亿美元，到 2033 年将达到 41.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 4.8%。

癌胚抗原 (CEA) 市场目前正经历显着成长，这主要得益于各种癌症（尤其是结直肠癌）发病率的上升，而大肠直肠癌正是 CEA 检测的主要应用领域。人们对癌症早期检测和后续观察的日益关注，导致对可靠肿瘤标记（例如 CEA）的需求不断增长。全球癌症发生率的上升推动了对先进诊断工具的需求，CEA 已被广泛应用于常规筛检。此外，免疫检测和生物标记发现等诊断技术的不断进步，正在提高 CEA 检测的准确性和效率。然而，成本方面的挑战依然存在，尤其是在医疗预算有限的地区，这可能会限制新兴经济体的市场扩张。

癌胚抗原市场驱动因素

包括大肠直肠癌在内的多种癌症发生率不断上升，显着增加了对可靠肿瘤标记（例如癌胚抗原 (CEA)）的需求。 CEA 检测能够早期发现癌症并监测其进展，这在患者管理和治疗效果中发挥着至关重要的作用。医护人员和患者都在寻求更精准的诊断工具以改善早期检测，这推动了 CEA 在临床实践中日益重要的地位和广泛的应用。人们对 CEA 在肿瘤学领域价值的认识不断提高，是推动该市场扩张的主要因素。

限制癌胚抗原（CEA）市场的因素

癌胚抗原 (CEA) 市场面临的主要限制因素在于 CEA 检测相关的经济障碍。价格承受能力是亟待解决的问题，尤其是在医疗资源有限的地区，这影响了该检测的广泛应用。此外，市场上还存在其他诊断方法的竞争，例如先进的影像技术和液态生物检体，这可能会导致人们的关注点和资源从 CEA 检测转移开来。这些因素共同构成了 CEA 市场成长和渗透的挑战性环境，限制了其在医疗诊断领域的整体潜力。

癌胚抗原（CEA）市场趋势

由于先进技术与调查方法的融合日益增强，癌胚抗原 (CEA) 市场呈现显着的成长趋势。这包括诊断技术的改进，例如创新免疫检测的开发和生物标记发现的进展，这些都显着提高了 CEA 检测的准确性和性能。此外，CEA 的应用范围正在从传统的癌症诊断扩展到其他领域，探索其在各种治疗领域和个人化医疗中的应用潜力。技术和应用的拓展，以及应用范围的扩大，正在推动癌症诊断市场的成长，并提升整体标准。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

F. Hoffmann-La Roche Ltd.（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Quest Diagnostics Incorporated（USA）
Abbott Laboratories（USA）
Merck KGaA（Germany）
Laboratory Corporation of America Holdings（USA）
Siemens Healthineers AG（Germany）
Bio-Rad Laboratories, Inc.（USA）
Creative Diagnostics（USA）
Aviva Systems Biology Corporation（USA）
Omega Diagnostics Ltd.（UK）
RayBiotech, Inc.（USA）
Boster Biological Technology（USA）
Diazyme Laboratories Inc.（USA）
GenScript Corporation（USA）
Lee BioSolutions（USA）
Danaher Corporation（USA）
Novartis AG（Switzerland）
Agilent Technologies, Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35H2233

Carcinoembryonic Antigen Market size was valued at USD 2.72 Billion in 2024 and is poised to grow from USD 2.86 Billion in 2025 to USD 4.16 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The Carcinoembryonic Antigen (CEA) market is currently experiencing significant growth, driven by the rising incidence of various cancers, particularly colorectal cancer, which is a primary application for CEA testing. With a growing focus on early cancer detection and monitoring, the demand for reliable tumor markers like CEA is on the rise. The increasing global prevalence of cancers has heightened the need for advanced diagnostic tools where CEA is prominently utilized in routine screenings. Furthermore, ongoing advancements in diagnostic technologies, such as immunoassays and biomarker discovery, are enhancing the precision and efficiency of CEA testing. However, cost-related challenges persist, particularly in regions with constrained healthcare budgets, potentially limiting market expansion in emerging economies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Carcinoembryonic Antigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Carcinoembryonic Antigen Market Segments Analysis

Global Carcinoembryonic Antigen Market is segmented by Type, Gender, Product, Test, End User and region. Based on Type, the market is segmented into Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Thyroid Cancer and Others. Based on Gender, the market is segmented into Male and Female. Based on Product, the market is segmented into CD66a, CD66b, CD66c, CD66d, CD66e and CD66f. Based on Test, the market is segmented into Molecular Test and Serology Test. Based on End User, the market is segmented into Hospitals & Clinics, Research Institutes, Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Carcinoembryonic Antigen Market

The increasing prevalence of various cancers, particularly colorectal cancer, has significantly heightened the demand for reliable tumor markers such as Carcinoembryonic Antigen (CEA). The ability to detect cancer early and monitor its progression through CEA testing plays a vital role in patient management and treatment outcomes. As healthcare professionals and patients alike seek more accurate diagnostic tools to improve early detection, the importance of CEA in clinical settings has intensified, driving its widespread adoption. This growing recognition of the value of CEA in oncology is a key factor contributing to the expansion of this market.

Restraints in the Carcinoembryonic Antigen Market

A significant limitation in the Carcinoembryonic Antigen (CEA) market stems from the financial barriers associated with CEA testing. The issue of affordability is particularly pressing in regions with limited healthcare funding, which impacts widespread access and adoption of these tests. Additionally, the market faces competition from alternative diagnostic methods, including advanced imaging techniques and liquid biopsies, which may draw attention and resources away from a concentrated focus on CEA testing. These factors collectively contribute to a challenging environment for the growth and penetration of the CEA market, limiting its overall potential in healthcare diagnostics.

Market Trends of the Carcinoembryonic Antigen Market

The Carcinoembryonic Antigen (CEA) market is witnessing a notable trend driven by the rising integration of advanced technologies in testing methodologies. This includes enhancements in diagnostic technologies, such as the development of innovative immunoassays and advancements in biomarker discovery, which significantly elevate the precision and performance of CEA tests. Furthermore, there is an expanding scope of CEA applications beyond traditional cancer diagnostics, exploring its potential in various therapeutic areas and personalized medicine. This convergence of technology and expanded utility is fueling growth and elevating the overall standards of cancer diagnostics within the market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Carcinoembryonic Antigen Market Size by Type & CAGR (2026-2033)

Market Overview
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Thyroid Cancer
Others

Global Carcinoembryonic Antigen Market Size by Gender & CAGR (2026-2033)

Market Overview
Male
Female

Global Carcinoembryonic Antigen Market Size by Product & CAGR (2026-2033)

Market Overview
CD66a
CD66b
CD66c
CD66d
CD66e
CD66f

Global Carcinoembryonic Antigen Market Size by Test & CAGR (2026-2033)

Market Overview
Molecular Test
Serology Test

Global Carcinoembryonic Antigen Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Research Institutes
Surgical Centers
Others

Global Carcinoembryonic Antigen Market Size & CAGR (2026-2033)

North America (Type, Gender, Product, Test, End User)
- US
- Canada
Europe (Type, Gender, Product, Test, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Gender, Product, Test, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Gender, Product, Test, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Gender, Product, Test, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aviva Systems Biology Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omega Diagnostics Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RayBiotech, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boster Biological Technology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Diazyme Laboratories Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lee BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments